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Objectives: To retrospectively evaluate the impact on daily activities of transcatheter closure of patent
foramen ovale (PFO) versus medical therapy in patients with migraine and to analyze the role of the
residual shunt after PFO closure.
Background: While non-controlled observational studies reported an improvement of migraine after PFO
closure, a randomized trial has shown no beneﬁt of such an intervention. The role of residual shunt after
PFO closure is also poorly known.
Methods: Out of 217 patients with migraine and echocardiographic evidence of PFO, 89 were managed
with percutaneous PFO closure (Group A) while 128 were medically treated (Group B). All MIDAS ques-
tionnaires were obtained at the ﬁrst evaluation and repeated at least 6 months after the index evaluation
or after the PFO closure. All the patients were also asked to give a subjective estimate of their migraine
status. A postprocedural transcranial Doppler study was available in 70 patients in Group A.
Results: The mean basal MIDAS score did not differ between the two groups (p=0.859). After a mean
follow-up (FU) of 1399±982 days the MIDAS score decreased signiﬁcantly in both groups (Group A
baseline vs FU, p<0.001; Group B baseline vs FU, p<0.001), but no differences were observed between
groups (p=0.204). However a signiﬁcantly higher number of Group A patients reported a perceived
clinical beneﬁt or the disappearance ofmigraine compared toGroup B (p<0.001). Patientswithmoderate
or severe residual right to left shunt were no more likely to have an higher MIDAS score or to complain
of migraine than those with mild or no shunt.
Conclusions: Although the overall evolution of migraine is not signiﬁcantly different, the abolition of
migraine occurs in a larger proportion after PFO closure.
© 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.ntroduction
Migraine affects more than 10% of the general population
nd is associated with signiﬁcant morbidity, loss of productivity
nd high health care costs [1]. A causal relationship has been
ypothesized between patent foramen ovale (PFO) and migraine
∗ Corresponding author at: Division of Cardiology, Department of Medical Sci-
nces, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino,
orso A. M. Dogliotti 14, 10126 Torino, Turin, Italy.
el.: +39 0116636165/3337852731; fax: +39 0116967053.
E-mail address: luigi.biasco@gmail.com (L. Biasco).
ttp://dx.doi.org/10.1016/j.jjcc.2014.02.023
914-5087/© 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.based on the evidence that a PFO can be found in nearly half the
sufferers of migraine with aura [2–4], and that the prevalence of
migraine in stroke patients with PFO is high, ranging between 27%
and 52% [5–7]. After the initial report by Wilmshurst et al. [8],
many other non-controlled observational studies have described
an improvement of migraine after PFO closure [9–16]. However,
the MIST study, a randomized, double blind, shame procedure
controlled trial, did not show any beneﬁt of PFO closure in terms of
cessation or reduction of episodes, severity of attacks, and change
in the characteristics of migraine [17]. Moreover, a recent review
by Sathasivam and Sathasivam stated that currently PFO closure
cannot be recommended as a routine treatment formigraine for the
debatable pathophysiological relevance, the inconclusively proven
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fﬁcacy and the possible complication related to PFO occlusion,
ighlighting the need for further research in this ﬁeld [18].
The purpose of our study was to retrospectively evaluate the
mpact of PFO closure vs standard medical therapy on migraine
everity. Since the effect of residual shunt after PFO closure is con-
roversial [10,17], we also analyzed the relationship between the
esidual shunt after percutaneous PFO closure and the evolution of
he disease in migraineurs.
aterials and methods
atients selection
BetweenDecember 1999and June2012, of 835patients referred
o our outpatient clinic for PFO-related conditions, 217 patients
ulﬁlled the following inclusion criteria:
clinical history of migraine diagnosed by a neurologist according
to the International Classiﬁcation ofHeadacheDisorders [19], and
echocardiographic evidence of PFO.
The primary referral diagnosis was migraine with or without
ura in 148 (68.2%), stroke in 42 (19.3%), transient ischemic attack
TIA) in 24 (11.1%), and peripheral embolism in 3 (1.4%).
linical and echocardiographic work-up
A detailed history of symptoms and drug therapy, a complete
hysical examination, and a transthoracic and transesophageal
chocardiogram (TEE) to conﬁrm thediagnosis of PFOwas obtained
n all patients. All shunt evaluations were made with a multi-
lane TEE probe using agitated saline solution as a contrast agent.
PFO with RLS (spontaneous or during Valsalva maneuver) was
eﬁned as the passage of at least ﬁve microbubbles from the right
o the left atrium across the interatrial septum within three cardiac
ycles from intravenous saline injection. An atrial septal aneurysm
eﬁned as a ﬂapping movement of the interatrial septum during
he cardiac cycle with an excursion ≥1 cm was evident in 29 out
f 89 subjects (32.5%) who underwent a percutaneous occlusion.
fter PFO closure, power M-mode transcranial color Doppler (TCD)
canning performed through the temporal approach after agitated
aline injection was used as a screening technique to assess the
resence and degree of the residual RLS. The shunt on TCD was
able 1
asal clinical characteristics.
Interventional Tx (Group A
Total number 89
Mean age, years 46.4±12.7
Sex, n (%)
Men 22 (24.7)
Women 67(75.3)
Referral diagnosis
Secondary prevention of paradoxical embolism, n (%)
Stroke 33 (37.1)
Transient ischemic attack 19 (21.3)
Peripheral embolism 2(2.2)
Migraine only 35 (39.3)
Type of migraine
With aura, n (%) 67 (75.3)
Without aura, n (%) 22 (24.7)
MIDAS score 47.5±66.3
Pharmacological treatment
None, n (%) 24 (26.9)
≥1 drug, n (%) 65 (83.1)
Baseline drug consumption, per month 5.5±7.5
old is used to highlight statistically signiﬁcant parameters.ology 64 (2014) 390–394 391
graded as absent or mild [0–10 Micro Embolic Signals (MES)],
moderate (>10 MES up to a shower or curtain pattern only after
Valsalva), severe (basal shower or curtain pattern).
Evaluation of migraine
Migraine severity was estimated in all patients at baseline
using the validated Migraine Disability Assessment Questionnaire
(MIDAS) score [20]. In brief this ﬁve-point questionnaire evaluates
the burden of migraine episodes in the past 3 months, their impact
on working, social, leisure and family activities and the perceived
pain.
Management strategies
After a thorough explanation and discussion with the patients
of knowns and unknowns concerning the risk–beneﬁt ratio of
PFO closure vs medical therapy, PFO closure was recommended
to 89 patients (Group A), while the remaining 128 were advised
to carry on the medical treatment (Group B). More in detail we
proposed PFO closure in patients with migraine associated with
previous suspected paradoxical embolic events, while closure was
proposed to “pure migraineurs” without history of previous para-
doxical embolism only in the case of severely disabling symptoms
not controlled by multiple therapy. Migraine associated with dis-
abling symptoms and refractory to conventional medical therapy
was the only reason to recommend PFO closure in 35 patients.
In the remaining54 theprimary referral diagnosiswasa cerebral
or peripheral embolic event (Table 1).
Percutaneous closure of PFO
Under local anesthesia, through a femoral venous access, the
PFO was crossed with a multipurpose catheter. An exchange
guidewire was then advanced to the left superior pulmonary vein.
A long sheath was then advanced into the left atrium and the
device was implanted and released under ﬂuoroscopic guidance
in a 50–60◦ left anterior oblique projection. Devices implanted are
listed in Table 2. Neither transesophageal nor intracardiac echocar-
diography was routinely employed. All procedures were free of
acute complications, in particular none of the patients experienced
seriousbleeding requiring transfusion.Discharge therapyconsisted
of aspirin 100mgdaily for 6months and clopidogrel 75mgdaily for
) Medical Tx (Group B) P value
128
47.1±12.3 0.684
0.030
17 (13.3)
111 (86.7)
9 (7.0) <0.001
5 (2.3)
1 (0.8)
113 (88.2)
82 (64.1) 0.039
46 (35.9)
46.1±49.6 0.859
11 (8.6) <0.001
117 (91.4)
8.1±8.4 0.020
392 L. Biasco et al. / Journal of Cardi
Table 2
Description of different devices used.
Device tipe
Amplatzer PFO occluder
18mm 8
25mm (Cribriform) 42 (3)
30mm (Cribriform) 3 (4)
35mm (Cribriform) 11 (1)
Amplatzer ASD occluder 3
Cardia PFO occluder
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30mm 2
Others 7
months. Infectious endocarditis prophylaxis was also advised for
ix months.
ollow up
All patients were seen at 6 and 12 months and yearly thereafter.
ollow-up time was deﬁned as the time interval between the ﬁrst
linical evaluation and the date of the last available follow-up visit.
repeated MIDAS questionnaire was obtained 6 months after the
rst evaluation or transcatheter closure of PFO. We also evaluated
he subjective perceived beneﬁt by asking the patients whether
hey felt better, unchanged or worse compared to the ﬁrst assess-
ent. Seventy of the 89 patients who underwent percutaneous
losure had a TCD study repeated 6 months after the procedure
o assess the presence of a residual shunt.
tatistical analysis
Descriptive analysis was performed using mean± standard
eviation for continuous variables and counts and percentages for
on-continuous variables. The normality of distribution of contin-
ous variables was evaluated by the Kolmogorov–Smirnov test,
nd therefore compared with independent sample Student t, one
ay ANOVA or uncorrected chi square method when appropriate.
ll probability values were considered to be signiﬁcant at a value
0.05.esults
The baseline characteristics of study subjects are reported in
able 1.While agewas similar, thereweremorewomen inGroup B.
able 3
ollow-up data.
Interventional (Group
Follow-up MIDAS score 17.2±33.8
Subjective evaluation
Better, n (%) 74 (83.1)
Equal, n (%) 10 (11.2)
Worse, n (%) 5 (5.7)
Patients with migraine with aura, n 67
Better, n (%) 54 (80.5)
Equal, n (%) 10 (14.9)
Worse, n (%) 3 (4.6)
Reported resolution of migraine, n 36 (53.7)
Patients with migraine without aura, n 22
Better, n (%) 20 (90.9)
Equal, n (%) 0 (0)
Worse, n (%) 2 (9.1)
Reported resolution of migraine, n 10 (45.4)
Pharmacological treatment
None, n (%) 42 (47.2%)
≥1 drug, n (%) 47 (52.8%)
Follow-up drug consumption, per month 2.5±5.8ology 64 (2014) 390–394
Patientswho underwent PFO closure hadmore frequently a history
of presumed paradoxical embolism and suffered from migraine
with aura compared to Group B. The MIDAS score did not differ
between two groups. A larger proportion of Group A subjects were
not taking any therapy. They also consumed a lower amount of
drugs per month, compared to group B. Among group A patients
a lower MIDAS score was evident in subjects with history of
cerebral or peripheral embolism if compared to pure migraineurs
(34.5±40.8 vs 67.5±90.1; p<0.001).
After a mean follow-up 1399±982 days, a signiﬁcant reduc-
tion of the MIDAS score was observed in both groups (Group A
47.5±66.3 vs 17.2±33.8; p<0.001; and Group B 46.1±49.6 vs
26.3±38.2; p<0.001), but no differences were observed between
groups (p=0.204; Table 3).
A subjective improvement was perceived by both Group A and
B patients, but the percentage of subjects who reported a beneﬁt
was greater in the group who had their PFO closed compared to
those in medical therapy (83.1% vs 51.6%; p<0.001; Table 3).
Migraine disappeared in 46 (51.6%) out of 89 patients with PFO
closed and only in 31 (24.2%) out of 128 patients who contin-
ued with medical treatment (p<0.001). The evolution of migraine
according to the presence/absence of aura is reported in Table 3.
A change in the pattern of drug therapy was also observed
(Table 3). A substantial proportion of patients discontinued all ther-
apy in both groups: almost half of Group A patientswere not taking
any medication compared to one out of four Group B patients.
Postprocedural TCD was available for 70 patients: RLS was
absent or mild in 54, moderate in 13 and severe in 3. In two of
these three latter patients, TEE was negative; since they had a
very little or no migraine left, no further intervention was rec-
ommended. In the remaining patient, because TEE conﬁrmed a
substantial residual shunt, a second cardiac catheterization was
performed. No residual shunt was found across the interatrial sep-
tumor the device both by conventional cavography and by contrast
echocardiography with injection in the inferior caval vein. How-
ever, the injection of echocontrast directly into the pulmonary
artery revealed a transpulmonary shunt.
In our population, the presence of ASA was not associated with
a moderate or severe residual shunt (p=0.541).
The proportion of patientswithMIDAS score >20was not signif-
icantly different among subjects with different degrees of residual
shunts (Fig. 1). The percentage of subjects who perceived a ben-
eﬁt after PFO closure was not different in patients with no or
mild (85.0%) comparedwith thosewithmoderate or severe (87.5%)
A) Medical Tx (Group B) P value
26.3±38.2 0.204
66 (51.6) <0.001
49 (38.3)
13 (10.1)
82
39 (47.5)
35 (42.7)
8 (9.8)
20 (24.4)
46
27 (58.7)
14 (30.4)
5 (10.9)
11 (23.9)
32 (25.0) <0.001
96 (75.0)
5.2±7.2 0.003
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Fig. 1. Distribution MIDAS score <20 and ≥20 accordingly to residual right to left
shunt.
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mig. 2. Subjectively perceived clinical beneﬁt after PFO closure accordingly to resid-
al right to left shunt.
esidual shunt (p=0.961; Fig. 2). Even at follow-up, in Group A sub-
ects a signiﬁcantly lower MIDAS score was evident in patients
reated for the secondary prevention of paradoxical embolism
f compared to pure migraineurs (MIDAS score 13.2±26.89 vs
3.25±41.99; p=0.009). Among those patients 27 out of 35 (77.1%)
ure migraineurs and 47 out of 57 patients with migraine associ-
ted with embolic event reported a subjective improvement of the
igraine after intervention (p=0.224).
Patients whose migraine became worse after PFO closure were
ll females with an age between 37 and 48 years, three out of
ve had migraine with aura, while the remaining referred only
igraine, in all but one the postprocedural TCD was negative,
xcluding a possible deterministic role of PFO.
During follow-up no deaths or strokes were observed. In Group
one patient who had previous history of paradoxical embolism
ssociatedwithmigraine underwent surgical removal of the device
ue to endocarditis, while in Group B one patient experienced a
ransient ischemic attackduring anepisodeof palpitations and thus
as implanted with a loop recorder for the suspect of paroxysmal
pisodes of atrial ﬁbrillation.
iscussionSince the ﬁrst observation of Wilmhshurst et al. in 2000 [8], a
umber of retrospective studies reported a signiﬁcant reduction in
igraine burden after percutaneous PFO closure [9–13]. The caseology 64 (2014) 390–394 393
control study by Anzola et al. [14] also found an overall improve-
ment of migraine severity. However, the MIST trial [17], which was
a randomized, sham controlled study, failed to demonstrate a def-
inite superiority of PFO closure on migraine cessation or change in
severity. Nevertheless, even in this negative study a few patients
reported the complete resolution of their migraine.
We found that a signiﬁcant reduction of the burden of migraine
and of its impact on work, social and leisure activities occurred
both in patients who had the PFO closed and in those who contin-
ued with medical treatment at a relatively long follow-up interval.
The MIDAS score was not different between the two groups. How-
ever, the number of patients in whom migraine disappeared was
signiﬁcantly higher in Group A than in Group B patients.
Also, when asked whether they felt better, worse or unchanged,
the patients who had their PFO closed were more likely to consider
themselves better than those on medical therapy alone.
Our work cannot ultimately resolve the issues of the sponta-
neous changes in the natural history of migraine [20,21] and of a
possible placebo effect, which is known to reduce the frequency of
migraine by up to 70% [19].
We concurwith the results of theMIST trial; in that the presence
and degree of a residual shunt do not correlate with the evolution
of migraine.
Limitations
The retrospective nature of our work may have introduced
patient and treatment selection biases.
Moreover the presence of a heterogeneous population in terms
of previous central or peripheral embolisms may inﬂuence the
results.
Conclusions
Our data suggest that the evolution of migraine is not pre-
dictably inﬂuenced by transcatheter PFO closure when compared
withmedical treatment.However,manypatients do report a signif-
icant improvement after PFO closure or the complete resolution of
migraine. This suggests that a percentage of migraineurs may ben-
eﬁt from an interventional strategy. Unfortunately, capable tools
to select a priori this population are still lacking. Finally, the pres-
ence of residual shunt is not associated with a worse evolution of
migraine after PFO closure.
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